BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

AllergEase Research Study Presented At Scripps 11th Annual Natural Supplements Conference


2/6/2014 8:36:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DANVILLE, Va.
, Feb. 6, 2014 /PRNewswire/ -- AllergEase, Inc. revealed its company's positive research study results for its core product, the Honey Lemon Lozenge, at the Scripps 11th Annual Natural Supplements Conference on Monday in San Diego.

The study, conducted by global CRO Medicus Research, revealed positive results for AllergEase®. The product is designed to reduce the symptoms of seasonal and environmental allergies, which affect approximately 20 million individuals in the U.S.

"Controlling allergies has been a topic of discussion for years. It's been a complex and challenging phenomenon for scientists," said Principal Investigator Jay Udani, M.D., CEO of Medicus Research. "Through our clinical research studies, we were able to show that the product improved nasal airflow and leads to less sneezing."

The randomized, double-blind crossover clinical trial concluded that consumption of the study product during acute antigen exposure was safe and resulted in decreased sneezing and attenuation of the expected drop in nasal airflow. These results suggest that consumption of AllergEase® during acute antigen exposure may result in faster recovery.

The conference selects the most relevant abstracts that present a concise, clinically relevant overview of their evidence-based research.

"We were very excited to learn the results of Medicus Research's clinical study," said Omar Javery, M.D., who developed the AllergEase® lozenge. "Allergy sufferers now have a proven, all-natural alternative to help them get back to enjoying their lives, minus the side-effects that often accompany allergy products."

For a copy of the abstract or media inquiries, please contact press@aedrops.com.

About AllergEase, Inc.

Headquartered in Danville, Virginia, AllergEase, Inc. is a privately-owned company. Its core product, the Original Honey Lemon Lozenges, is made from an all-natural formula of 4 herbs, menthol and organic honey was launched in February 2012. AllergEase is sold in Walgreens nationwide and other select retailers. Visit us on the web at www.allergease.com

SOURCE AllergEase, Inc.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES